Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation
Molecules · 2023
DOI: 10.3390/molecules28166035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Wenqi Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Hai…. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinases, Heart Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Program, the National Natural Science Foundation of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
(1)
Background
Heart failure (HF) is the final stage of multiple cardiac diseases, which have now become a severe public health problem worldwide. β-Adrenergic receptor (β-AR) overactivation is a major pathological factor associated with multiple cardiac diseases and mediates cardiac fibrosis and inflammation. Previous research has demonstrated that Bruton’s tyrosine kinase (BTK) mediated cardiac fibrosis by TGF-β related signal pathways, indicating that BTK was a potential drug target for cardiac fibrosis. Zanubrutinib, a second-generation BTK inhibitor, has shown anti-fibrosis effects in previous research. However, it is unclear whether Zanubrutinib can alleviate cardiac fibrosis induced by β-AR overactivation; (2)
Methods
In vivo: Male C57BL/6J mice were treated with or without the β-AR agonist isoproterenol (ISO) to establish a cardiac fibrosis animal model; (3)
Results
In vivo: Results showed that the BTK inhibitor Zanubrutinib (ZB) had a great effect on cardiac fibrosis and inflammation induced by β-AR. In vitro: Results showed that ZB alleviated β-AR-induced cardiac fibroblast activation and macrophage pro-inflammatory cytokine production. Further mechanism studies demonstrated that ZB inhibited β-AR-induced cardiac fibrosis and inflammation by the BTK, STAT3, NF-κB, and PI3K/Akt signal pathways both in vivo and in vitro; (4) Conclusions: our research provides evidence that ZB ameliorates β-AR-induced cardiac fibrosis and inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, China.
- Tianjin International Joint Academy of Biomedicine, Tianjin 300457, China.
- Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
ORCID-Profile: Wenqi Li, Honggang Zhou
Förderung
- Shenzhen Science and Technology Program
- the National Natural Science Foundation of China
- National Natural Science Foundation of China
Zitieren
APA
Li, W., Zhu, S., Liu, J., Liu, Z., Zhou, H., Zhang, Q., Yang, Y., Chen, L., Guo, X., Zhang, T., Meng, L., Chai, D., Tang, G., Li, X., & Yang, C. (2023). Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation. Molecules. https://doi.org/10.3390/molecules28166035
Vancouver
Li W, Zhu S, Liu J, Liu Z, Zhou H, Zhang Q, et al. Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation. Molecules. 2023. doi:10.3390/molecules28166035
BibTeX
@article{Li2023,
author = {Li, Wenqi and Zhu, Shuwen and Liu, Jing and Liu, Zhigang and Zhou, Honggang and Zhang, Qianyi and Yang, Yue and Chen, Li and Guo, Xiaowei and Zhang, Tiantian and Meng, Lingxin and Chai, Dan and Tang, Guodong and Li, Xiaohe and Yang, Cheng},
title = {Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28166035}
}
EUVIMED